Efalizumab: a review of events reported during clinical trials and side effects.
about
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.Efalizumab-induced severe thrombocytopenia can be resolvedBiologics in dermatologic therapy - an update.Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.Biologics in the management of psoriasis.The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.Biological therapy and nail psoriasis.Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma.Efalizumab discontinuation: a practical strategy.Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.Biological agents for the treatment of uveitis.Serum sickness-like reaction associated with efalizumab.DRESS syndrome caused by efalizumab.Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1.LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells.Efalizumab in routine use: a clinical experience.Efalizumab-induced hypertrichosis.Exacerbation of psoriasis under efalizumab therapy.EfalizumabLong-term treatment of plaque psoriasis with efalizumab: an Italian experience
P2860
Q33261650-8E5FEC6E-4CF4-4A05-AB3F-92E0BE3FE77EQ33385978-DBDCF1BA-48BE-4A6E-A726-BDAE5FDC8A60Q33607620-9BD0A4BA-C341-447A-A4AA-DF19B5E5BB8DQ34026630-D2781401-FC56-4B6D-A25A-9695F3686E15Q34620257-1EF3F731-A5A7-4741-B956-3485E82C67CDQ36653650-31E37186-B531-48C3-8503-8D1795EC441DQ36777978-0361093C-7660-483D-8DFB-6C0418ECD855Q36955887-FA5528D2-2322-4540-AA9D-749F164FFBECQ37490929-4D96B40B-0194-4CFC-8C33-255D46B27692Q37607419-99835EAA-2FFD-4B0F-B6A0-AC2BFABF6042Q37984565-CD164E5B-914C-4965-A9C9-42635DAB39F2Q40397901-5BA89D73-4E19-4E2A-92E3-5B3824C69B02Q40434235-7BBD9671-3F2A-49D9-B176-2A571E677CBBQ41559765-BE86C1B2-5DE2-486E-B421-F7E5F9C298CCQ41892335-42B3FAE1-1DC6-465B-BBBE-AC85FB27F2BAQ43136846-B938AA09-65D3-46DE-8CCC-A1D774EC3158Q44124198-12655F55-7110-474E-9DD7-985A48A312B8Q46684623-85F0E824-00C4-4D32-AE16-EFBCD8AC4E45Q51759813-F18226A3-3F2A-4C6A-827F-910C26528F54Q58434864-3DF6B0D6-4EC1-4C2A-A8D5-26AC2CEF62F1Q58434978-C9E2E00A-2C17-4EF8-BB26-C80C0F62DFAF
P2860
Efalizumab: a review of events reported during clinical trials and side effects.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efalizumab: a review of events reported during clinical trials and side effects.
@ast
Efalizumab: a review of events reported during clinical trials and side effects.
@en
type
label
Efalizumab: a review of events reported during clinical trials and side effects.
@ast
Efalizumab: a review of events reported during clinical trials and side effects.
@en
prefLabel
Efalizumab: a review of events reported during clinical trials and side effects.
@ast
Efalizumab: a review of events reported during clinical trials and side effects.
@en
P356
P1476
Efalizumab: a review of events reported during clinical trials and side effects.
@en
P2093
Noah Scheinfeld
P304
P356
10.1517/14740338.5.2.197
P407
P577
2006-03-01T00:00:00Z